Company newsMRNA
Explain this story: MAIA Biotechnology expands pivotal Phase 3 THIO-104 NSCLC trial into Spain and Portugal
MAIA Biotechnology has secured regulatory approval from Spain's AEMPS and Portugal's INFARMED to enroll patients for its pivotal Phase 3 THIO-104 trial in non-small cell lung cancer (NSCLC). This expansion into new markets, which together account for approximately 30,000 new lung cancer cases annually, aims to broaden patient access to the investigational therapy and help the Chicago-based company meet its enrollment targets for a key interim survival analysis in 2027. THIO-104 is a first-in-class telomere-targeting agent, and the trial has already enrolled 65 patients with advanced NSCLC.
OtherDealroomSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
MAIA Biotechnology has secured regulatory approval from Spain's AEMPS and Portugal's INFARMED to enroll patients for its pivotal Phase 3 THIO-104 trial in non-small cell lung cancer (NSCLC). This expansion into new markets, which together account for approximately 30,000 new lung cancer cases annually, aims to broaden patient access to the investigational therapy and help the Chicago-based company meet its enrollment targets for a key interim survival analysis in 2027. THIO-104 is a first-in-class telomere-targeting agent, and the trial has already enrolled 65 patients with advanced NSCLC.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Published Sep 24, 2026, 02:57 ET · on this site +2d 22h